1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Nevro Corp.
  6. Summary
    NVRO   US64157F1030

NEVRO CORP.

(NVRO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
46.14(c) 47.4(c) 44.52(c) 44.44(c) 44.72 Last
824 376 744 332 615 266 1 015 919 642 017 Volume
-2.56% +2.73% -6.08% -0.18% +0.63% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 423 M - -
Net income 2022 -99,8 M - -
Net cash position 2022 95,4 M - -
P/E ratio 2022 -15,6x
Yield 2022 -
Sales 2023 476 M - -
Net income 2023 -71,7 M - -
Net cash position 2023 72,6 M - -
P/E ratio 2023 -22,2x
Yield 2023 -
Capitalization 1 564 M 1 564 M -
EV / Sales 2022 3,47x
EV / Sales 2023 3,13x
Nbr of Employees 945
Free-Float 96,2%
More Financials
Company
Nevro Corp. is a global medical device company, which is focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform being its an... 
More about the company
Ratings of Nevro Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NEVRO CORP.
05/17Citigroup Adjusts Nevro's Price Target to $68 From $78, Reiterates Buy Rating
MT
05/10TRANSCRIPT : Nevro Corp. Presents at Bank of America 2022 Healthcare Conference, May-10-20..
CI
05/05Citigroup Upgrades Nevro to Buy From Neutral; Price Target is $78
MT
05/05Piper Sandler Adjusts Nevro's Price Target to $64 From $65, Maintains Neutral Rating
MT
05/04NEVRO : Q1 Earnings Snapshot
AQ
05/04NEVRO CORP Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
05/04Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87.8M
MT
05/04TRANSCRIPT : Nevro Corp., Q1 2022 Earnings Call, May 04, 2022
CI
05/04NEVRO CORP : Results of Operations and Financial Condition (form 8-K)
AQ
05/04Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidan..
PR
05/04Nevro Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earni..
CI
04/22Careful Drafting And Crafting
AQ
04/13Truist Securities Assumes Nevro With Hold Rating, $80 Price Target
MT
04/11Nevro Corp. Announces Vale Will Not Stand for Reelection When His Current Term Expires ..
CI
More news
News in other languages on NEVRO CORP.
05/04Earnings Flash (NVRO) NEVRO annonce un revenu de 87,8 millions de dollars pour le premi..
05/04Nevro Corp. fournit des prévisions de bénéfices pour le deuxième trimestre de 2022 ; ré..
05/04Nevro Corp. annonce ses résultats pour le premier trimestre se terminant le 31 mars 202..
04/11Nevro Corp. annonce que Vale ne se représentera pas à la réélection lorsque son mandat ..
03/09ACHAT D'INITIÉS : Nevro
More news
Analyst Recommendations on NEVRO CORP.
More recommendations
Chart NEVRO CORP.
Duration : Period :
Nevro Corp. Technical Analysis Chart | NVRO | US64157F1030 | MarketScreener
Technical analysis trends NEVRO CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 44,44 $
Average target price 75,36 $
Spread / Average Target 69,6%
EPS Revisions
Managers and Directors
D. Keith Grossman Chairman, President & Chief Executive Officer
Roderick H. MacLeod Chief Financial Officer
David Caraway Chief Medical Officer
Christopher Christoforou Vice President-Technical Operations
Stephen Smith Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NEVRO CORP.-45.18%1 564
ABBOTT LABORATORIES-20.11%196 876
MEDTRONIC PLC-0.68%137 843
BECTON, DICKINSON AND COMPANY2.19%71 591
BAXTER INTERNATIONAL INC.-15.42%36 556
HOYA CORPORATION-26.33%36 134